This trial is studying the side effects of talimogene laherparepvec and radiation therapy in treating patients with newly diagnosed soft tissue sarcoma.
2 Primary · 7 Secondary · Reporting Duration: Up to 5 years
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: Talimogene Laherparepvec · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: